Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Notified -
Globe Newswire3-12-2025, 20:00
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules 17-04-2024, 13:00